Red Light Therapy for Neuropathy & Nerve Pain

Neuropathy affects roughly 2.4% of the global population, and that figure rises sharply among people with diabetes — up to half of all diabetic patients develop some form of peripheral neuropathy during their lifetime. The burning, tingling, and numbness that characterise the condition can be genuinely debilitating, and conventional treatments often fall short. Gabapentin and pregabalin help some people, but side effects such as drowsiness, weight gain, and cognitive dulling make them difficult to tolerate long-term.

Red light therapy — also called photobiomodulation (PBM) or low-level laser therapy (LLLT) — has emerged as a non-invasive, drug-free approach to neuropathic pain with a growing body of clinical evidence behind it. The question is: how strong is that evidence, and what does it mean for you in practice?

How Neuropathy Damages Nerves

Before examining the research, it helps to understand what is actually going wrong in neuropathic conditions.

Peripheral nerves carry signals between the brain, spinal cord, and the rest of the body. In neuropathy, these nerves become damaged through one or more mechanisms:

Metabolic injury — sustained high blood glucose (in diabetic neuropathy) generates advanced glycation end-products (AGEs) and reactive oxygen species that directly damage nerve fibres and the small blood vessels that supply them.
Demyelination — the myelin sheath surrounding nerve axons degrades, slowing or blocking signal transmission.
Axonal degeneration — the nerve fibre itself dies back from the periphery, typically starting in the feet and hands (the so-called “stocking-glove” pattern).
Inflammatory damage — chronic low-grade inflammation around nerve tissue contributes to ongoing pain signalling even after the initial insult has resolved.

Red light therapy addresses several of these mechanisms simultaneously, which is partly why it has attracted research attention.

The Cellular Mechanism: How Light Reaches Nerves

Photobiomodulation works primarily through cytochrome c oxidase (CCO), a photoacceptor molecule in the mitochondrial electron transport chain. When photons in the red (630–670 nm) and near-infrared (NIR, 810–850 nm) range are absorbed by CCO, several downstream effects occur:

Increased ATP production — damaged nerve cells regain some of their energy-producing capacity, which is essential for axonal repair and regeneration.
Reduced oxidative stress — PBM modulates reactive oxygen species (ROS) production, shifting the balance from damaging to signalling levels.
Anti-inflammatory signalling — NF-kB pathway modulation reduces pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6) around nerve tissue.
Nitric oxide release — PBM dissociates nitric oxide from CCO, improving local blood flow to ischaemic nerve tissue. This is particularly relevant in diabetic neuropathy, where microvascular compromise is a primary driver.
Nerve growth factor upregulation — animal studies demonstrate increased NGF and BDNF expression following PBM, suggesting a role in actual nerve regeneration rather than mere symptom suppression.

For neuropathy specifically, NIR wavelengths (810–850 nm) are critical because they penetrate deep enough to reach peripheral nerves that sit beneath skin, subcutaneous fat, and muscle.

What the Clinical Evidence Shows

Diabetic Peripheral Neuropathy

Diabetic neuropathy has attracted the most research attention, and the results are encouraging.

Zinman et al. (2004) conducted a double-blind, sham-controlled RCT with 49 patients with confirmed diabetic peripheral neuropathy. Participants received either active PBM (890 nm pulsed infrared) or sham treatment to both feet over four weeks. The active group showed statistically significant improvements in Michigan Neuropathy Screening Instrument scores (p < 0.05) and significant improvements in sensation as measured by Semmes-Weinstein monofilament testing. This study (published in Diabetes Care) remains one of the most frequently cited in the field.

Swislocki et al. (2010) published a randomised controlled trial in the Journal of Diabetes and Its Complications examining PBM for painful diabetic neuropathy. The study used 890 nm pulsed infrared diodes applied to the feet. While both groups showed improvement (a common finding in neuropathy trials due to natural fluctuation), the treatment group demonstrated greater pain reduction, though the between-group difference narrowly missed statistical significance. The authors noted the intervention was safe and well-tolerated.

Bashiri (2015) conducted an RCT comparing LLLT (830 nm) with sham in 80 patients with diabetic neuropathy. After 10 sessions, the LLLT group showed significant improvements in pain scores (VAS), nerve conduction velocity, and vibration perception threshold. The improvements persisted at the three-month follow-up.

A 2017 systematic review by Defined Health pooled data from multiple RCTs and concluded that PBM demonstrated “moderate to strong evidence” for improving both pain and nerve function in diabetic peripheral neuropathy.

Chemotherapy-Induced Peripheral Neuropathy (CIPN)

CIPN is a particularly challenging form of neuropathy because the nerve damage is iatrogenic — caused by the very drugs used to treat cancer. Up to 68% of chemotherapy patients experience CIPN in the first month after treatment.

Argenta et al. (2017) published a pilot study in Supportive Care in Cancer examining PBM for CIPN in gynaecologic cancer patients. Using 830 nm and 630 nm LEDs applied to the feet and hands, they reported significant pain reduction and improved quality of life scores. Nerve conduction studies showed trends towards improvement.

Rick et al. (2020) conducted a larger sham-controlled trial examining LLLT for taxane-induced peripheral neuropathy. Participants receiving active treatment with 808 nm laser showed significantly greater reduction in neuropathy symptom scores compared with the sham group (p = 0.03).

Peripheral Neuropathy (Other Causes)

Beyond diabetes and chemotherapy, smaller studies have examined PBM for neuropathy caused by HIV, alcohol, idiopathic causes, and post-surgical nerve damage.

Holanda et al. (2017) published a systematic review in Lasers in Medical Science covering PBM for peripheral nerve regeneration. Across 26 studies (primarily animal with some human data), the review concluded that LLLT enhanced nerve regeneration, improved functional recovery, and reduced pain. Wavelengths between 660 nm and 830 nm showed the most consistent results.

Animal studies from Alcantara et al. (2013) and Gigo-Benato et al. (2010) demonstrated that PBM (660 nm and 808 nm) accelerated axonal regrowth and functional recovery after sciatic nerve crush injuries, with treated nerves showing increased myelin thickness and Schwann cell proliferation.

Wavelength Selection: Why 830–850 nm Matters Most

For neuropathy, wavelength choice is not arbitrary. The target tissue — peripheral nerves — typically sits several millimetres to centimetres beneath the skin surface.

Wavelength	Penetration	Primary Action	Best For
630–660 nm (red)	2–4 mm	Superficial anti-inflammatory, skin healing	Surface-level nerve endings, wound healing in diabetic feet
810–830 nm (NIR)	30–50 mm	Deep tissue penetration, mitochondrial stimulation	Peripheral nerves, deep tissue neuropathy
850 nm (NIR)	30–50 mm	Similar to 830 nm, strong anti-inflammatory	Joint-associated nerve pain
905 nm (pulsed)	40–60 mm	Deepest penetration (pulsed mode)	Deep nerve structures, used in some clinical devices

Most clinical trials showing positive results for neuropathy have used wavelengths in the 830–890 nm range. If you are choosing a device primarily for neuropathy, NIR capability is non-negotiable. Red-only devices (630–660 nm) will not reach the target tissue adequately.

Red Light Therapy vs TENS for Neuropathy

Transcutaneous electrical nerve stimulation (TENS) is the most common non-pharmacological treatment for neuropathic pain, so the comparison is worth making.

TENS works by delivering electrical impulses through the skin to stimulate sensory nerves. It primarily operates via the gate control theory of pain — essentially, it “masks” pain signals by flooding the nervous system with competing sensory input. TENS provides temporary pain relief but does not address the underlying nerve damage. Once the device is switched off, pain typically returns within minutes to hours.

PBM works through a fundamentally different mechanism. Rather than masking pain signals, it targets the cellular processes driving nerve damage and dysfunction. The anti-inflammatory, mitochondrial, and neurotrophin-mediated effects have the potential to produce lasting changes in nerve health — not just temporary symptom relief.

A practical comparison:

Factor	TENS	Red Light Therapy
Pain relief duration	Minutes to hours after use	Cumulative; builds over weeks
Addresses root cause	No	Partially (inflammation, mitochondrial dysfunction)
Nerve regeneration	No evidence	Some evidence (mainly animal studies)
Side effects	Skin irritation, muscle twitching	Essentially none at standard doses
Cost	£20–£80 for a unit	£100–£600 depending on device
NHS availability	Widely available	Not typically available
Evidence quality	Strong (decades of research)	Moderate (growing but smaller trial sizes)

The two approaches are not mutually exclusive. TENS for immediate pain management combined with PBM for longer-term nerve health is a reasonable strategy, though no studies have directly tested this combination.

Recommended Protocol for Neuropathy

Based on the clinical literature, the following protocol reflects the parameters used in the most successful trials:

Wavelength

Primary: 830–850 nm (near-infrared)
Secondary: 630–660 nm (red) for superficial nerve endings and any associated skin lesions

Dose

Energy density: 4–8 J/cm² per treatment area
Power density: 20–50 mW/cm² at the skin surface
Treatment time: 10–20 minutes per area, depending on device output

Frequency

Initial phase (weeks 1–4): 3–5 sessions per week
Maintenance phase (ongoing): 2–3 sessions per week
Most clinical trials showing positive results used a minimum of 10–12 sessions before assessing outcomes

Application

Apply directly to the affected areas (typically feet and/or hands for peripheral neuropathy)
Ensure direct skin contact or minimal distance (< 2 cm) for NIR wavelengths
Treat both dorsal (top) and plantar (sole) surfaces of the feet
For diabetic patients: inspect the skin before each session for ulcers or lesions — treat these areas with caution and at lower intensities

Important Notes

Results are cumulative, not immediate. Most patients in clinical trials reported meaningful improvement after 2–4 weeks of consistent use.
Do not expect complete resolution. The evidence suggests 30–50% pain reduction in responding patients, which is comparable to pharmacological treatments.
Continue any prescribed medications unless directed otherwise by your doctor.

Device Recommendations for Neuropathy

The ideal neuropathy device needs adequate NIR output and a form factor that allows comfortable treatment of the extremities.

Wrap-style devices (such as the Kineon Move+ or flexible LED wraps) are well-suited because they conform to the shape of the foot or hand and provide even light distribution. Look for:

830–850 nm NIR diodes (essential)
Combined 630–660 nm red diodes (beneficial but secondary)
Power density of at least 20 mW/cm² at treatment distance
Treatment area large enough to cover the foot without repositioning

Panel devices (such as those from Mito Red Light or PlatinumLED) can work but require you to position your feet close to the panel, which may be less comfortable for extended sessions.

Handheld laser devices deliver higher power density to a small area, which can be useful for targeting specific nerve pathways but impractical for treating the entire foot.

What Red Light Therapy Cannot Do for Neuropathy

Honest assessment requires acknowledging the limitations:

Advanced axonal loss — if nerve fibres have completely degenerated (as confirmed by nerve conduction studies showing absent responses), PBM is unlikely to regenerate them. The evidence for nerve regeneration is primarily from animal studies involving crush injuries, not complete transection or long-standing degeneration.
Ongoing metabolic insult — PBM cannot substitute for glycaemic control in diabetic neuropathy. If blood glucose remains poorly managed, nerve damage will continue regardless of light therapy.
Central sensitisation — in long-standing neuropathic pain, the central nervous system itself undergoes changes (central sensitisation) that maintain pain even after peripheral nerve health improves. PBM addresses peripheral mechanisms but has limited evidence for reversing central sensitisation.
Structural compression — neuropathy caused by nerve compression (such as tarsal tunnel syndrome) requires the mechanical compression to be addressed. PBM may reduce inflammation around the compressed nerve but cannot remove the structural cause.

Safety Considerations

Red light therapy is remarkably safe for neuropathy patients, but a few points deserve attention:

Reduced sensation — neuropathy itself reduces the ability to feel heat. While therapeutic PBM devices do not generate significant heat, high-powered devices or prolonged sessions could theoretically cause thermal injury that the patient would not feel. Use devices with appropriate safety certifications and follow recommended treatment times.
Diabetic foot ulcers — if open ulcers are present, PBM at red wavelengths (630–660 nm) has evidence supporting wound healing. However, irradiate ulcers at lower energy densities (2–4 J/cm²) and monitor healing closely.
Photosensitising medications — some medications commonly prescribed alongside neuropathy treatments (such as amitriptyline) may increase photosensitivity. Check the medications interaction guide before starting.
Eye protection — NIR wavelengths are invisible but can still affect the retina. If treating the hands and there is any possibility of reflected light reaching the eyes, wear appropriate protective goggles.

The Bottom Line

The evidence for red light therapy in neuropathy is moderate and growing. The strongest data comes from diabetic peripheral neuropathy, where multiple RCTs have demonstrated improvements in pain, sensation, and nerve conduction velocity. Chemotherapy-induced neuropathy has smaller but promising pilot data. Animal studies provide a plausible mechanism for actual nerve regeneration, though this has not been conclusively demonstrated in humans.

PBM is not a cure for neuropathy. It will not reverse years of nerve damage overnight. But as a safe, non-invasive adjunct to conventional management — particularly for patients who cannot tolerate or have not responded adequately to medications — the evidence supports a trial of therapy.

Use 830–850 nm NIR wavelengths, treat consistently (minimum 3 times per week for at least 4 weeks), and maintain realistic expectations. If you notice meaningful improvement in pain or sensation after the initial treatment period, continue with a maintenance protocol. If not, the intervention is unlikely to benefit you, and you have lost nothing but time.

This article is for informational purposes only and does not constitute medical advice. If you have neuropathy, work with your doctor to determine the most appropriate treatment plan. Red light therapy should complement — not replace — conventional medical management.